PFO
CBST

Pathstone Family Office’s CUBIST PHARMACEUTICALS INC CBST Stock Holding History

Pathstone Family Office’s Portfolio CBST Stock Details CBST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-200
Closed -$13K – 378
2013
Q3 		$13K Buy
+200
New +$12.1K 0.06% 167

Other funds holding CBST

BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Pathstone Family Office's CBST Position: Q4 2013 in Review

Pathstone Family Office sold out of CUBIST PHARMACEUTICALS INC (CBST) in Q4 2013, closing a stake of 200 shares — an estimated $13K sold.

Pathstone Family Office first reported a position in CBST in Q3 2013 and held it in 1 quarter. The position peaked at $13K in Q3 2013. 276 funds tracked by Wall St. Rank hold CBST as of Q4 2013.

  • Pathstone Family Office reported no remaining CUBIST PHARMACEUTICALS INC position as of Q4 2013 after selling out during the quarter.
  • Pathstone Family Office sold 200 CUBIST PHARMACEUTICALS INC shares in Q4 2013, an estimated $13K.
  • Pathstone Family Office first reported a position in CUBIST PHARMACEUTICALS INC in Q3 2013 and held it in 1 quarter.
  • Pathstone Family Office's CUBIST PHARMACEUTICALS INC position peaked at $13K in Q3 2013.
  • 276 funds tracked by Wall St. Rank held CUBIST PHARMACEUTICALS INC as of Q4 2013.

Based on Pathstone Family Office's 13F filing for Q4 2013, filed 4 Feb 2014.